Skip to main content
OpenTrials
Completed

NCT Number: NCT07564986

Relationship Between Serum Resistin Levels and Reduction in Visceral Fat in Patients Undergoing Sleeve Gastrectomy Due to Morbid Obesity

This study aims to investigate whether a specific protein in the blood, called resistin, can help doctors predict how much dangerous internal fat a patient will lose following weight loss surgery. Sleeve gastrectomy is a common and effective procedure that reduces the stomach's size to help patients lose weight and improve their metabolic health. Beyond just losing weight, it is vital to reduce visceral fat-the fat stored around internal organs-which is closely linked to inflammation and conditions like Type 2 Diabetes. Resistin is a marker known to contribute to insulin resistance and is typically higher in individuals with significant abdominal fat. By measuring resistin levels before surgery, we want to determine if this protein can serve as a guide to predict a patient's internal fat loss and overall metabolic recovery. Ultimately, this research could help healthcare providers better understand the hormonal changes that occur during weight loss and identify which patients may experience the most significant health improvements after the procedure.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Basaksehir Cam and Sakura City Hospital

Istanbul, Basaksehir, 34480, Turkey (Türkiye)

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients aged 18 to 75
  • International Classification of Diseases (ICD) code E66 diagnosis (obesity)
  • Patients who have given consent for sleeve gastrectomy
  • Patients who are suitable for general anesthesia

Exclusion criteria

  • Patients who did not give consent to be included in the study
  • Patients who are scheduled for surgery other than sleeve gastrectomy

Treatment and study plan

Laparoscopic sleeve gastrectomy

Procedure

Laparoscopic Sleeve Gastrectomy

Primary outcomes

  1. Change in body mass index at 8 months

    Time frame: 8 months after surgery

Secondary outcomes

  1. Change in visseral fat at 8 months

    Time frame: 8 months after surgery

  2. Change in basal metabolic rate at 8 months

    Time frame: 8 months after surgery

Sponsors and collaborators

Lead sponsor

Sercan YUKSEL, MD

Other Gov

Registry information

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
May 4, 2026
Registry last updated
May 4, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.